Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UCHL1 | P09936 | 4/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MPO | P05164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31014046 | 0.92 | UCHL1 (0.52) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL3902861 | 0.92 | UCHL1 (0.52) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL4556732 | 0.90 | UCHL1 (0.41) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL20571008 | 0.86 | UCHL1 (0.61) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL30147617 | 0.86 | UCHL1 (0.61) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL20571049 | 0.84 | UCHL1 (0.46) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL2885921 | 0.83 | NOTUM (0.47) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL3502782 | 0.83 | UCHL1 (0.45) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL13312002 | 0.83 | UCHL1 (0.45) | UCHL1KDM1AHDAC1HDAC6NOTUM | |
| SCHEMBL22048927 | 0.82 | HDAC1 (0.51) | UCHL1KDM1AHDAC1HDAC6NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| US-9981977-B2 | Asymmetric electrophilic fluorination using an anionic chiral phase-transfer catalyst | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-05-29 | — | — | US | disclosed |
| EP-2121638-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK SHARP & DOHME (US) | 2016-05-25 | — | — | EP | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2014-11-27 | — | — | US | disclosed |
| WO-2013096971-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | ANTHONY NEVILLE J | 2010-11-11 | — | — | US | disclosed |
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME LLC | 2008-11-06 | — | — | US | disclosed |
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME LLC | 2008-11-06 | — | — | US | disclosed |
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | MERCK SHARP & DOHME LLC | 2008-11-06 | — | — | US | disclosed |
| WO-2008076225-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| WO-2008076225-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MERCK & CO., INC. (US) | 2008-06-26 | — | — | WO | disclosed |
| EP-1414820-B1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | BOEHRINGER INGELHEIM CA LTD (CA) | 2008-02-13 | — | — | EP | disclosed |
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | ELI LILLY AND COMPANY PATENT DIVISION (US) | 2006-07-27 | — | — | US | disclosed |
| EP-1585731-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-19 | — | — | EP | disclosed |
| WO-2005023188-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-03-17 | — | — | WO | disclosed |
| WO-2004026837-A2 | HISTAMINE H3 RECEPTOR ANTAGONISTS, PREPARATON AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2004-04-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275097-A1 | Non-nucleoside reverse transcriptase inhibitors | RNGTT, RRM2B, RRM2 | UCHL1 3899/4885KDM1A 199/4885HDAC1 401/4885 |
| US-20100286192-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | RNGTT, RRM2B, RRM2 | UCHL1 3899/4885KDM1A 199/4885HDAC1 401/4885 |
| US-20140350253-A1 | ASYMMETRIC ELECTROPHILIC FLUORINATION USING AN ANIONIC CHIRAL PHASE-TRANSFER CATALYST | GFPT1, NUDT1, INF2 | UCHL1 4356/4885KDM1A 4376/4885HDAC1 3178/4885 |
| US-20060167046-A1 | Histamine h3 receptor antagonists, preparation and therapeutic uses | HRH3, HRH4, HRH2 | UCHL1 1609/4885KDM1A 281/4885HDAC1 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.